attention deficit hyperactivity disorder in adult

Novel non-Stimulant Shows Promise for Adult ADHD: Centanafadine Demonstrates Clinically Meaningful Enhancement Table of Contents Novel non-Stimulant Shows Promise for Adult ADHD: Centanafadine Demonstrates Clinically Meaningful Enhancement Centanafadine Shows Promise in ADHD Treatment: A New Approach to Symptom Management Understanding Centanafadine’s Impact on ADHD Symptoms Expanding the Research: Pediatric Trials Yield Positive Results safety Profile … Read more

LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and “clinically meaningful” for adult attention-deficit/hyperactivity disorder (ADHD), new research suggested. In a combined analysis of two phase 3 trials with a total of 859 adults, more patients who received the NDSRI had at least an … Read more